Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Drive Forward
Sort By
Newest First
Sign in
1 / 1
1 / 1
HIV Therapy
Merck Announces Week 96 Data from Pivotal Phase 3 DRIVE-FORWARD Study of Its Investigational HIV Therapy Doravirine
Merck & Co.
PR-M07-18-NI-083
Jul 25, 2018
